Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Congenital Hyperinsulinism Clear all
Terminated No phase listed Observational

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

NCT00078091
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

NCT00571324
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

NCT00443599
View directory record Official record
Conditions
Heart Defects, Congenital, Hyperglycemia
Interventions
Insulin, Usual Care
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 36 Months
Enrollment
989 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03941236
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
5 Weeks to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Androgen Administration on Inflammation in Normal Women

NCT01753037
View directory record Official record
Conditions
Hyperandrogenism
Interventions
Dehydroepiandrosterone (DHEA), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
7 Days to 364 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 26, 2026, 4:15 PM EDT
Available No phase listed Expanded access

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma
Interventions
18F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 26, 2026, 4:15 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes

NCT00231192
View directory record Official record
Conditions
Diabetes
Interventions
Repaglinide and Insulin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 20 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome

NCT03797222
View directory record Official record
Conditions
Hyperinsulinism-Hyperammonemia Syndrome
Interventions
Vitamin E
Dietary Supplement
Lead sponsor
Elizabeth A Rosenfeld
Other
Eligibility
1 Year to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Sep 26, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy

NCT04222101
View directory record Official record
Conditions
Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Insulin Resistance
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 26, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

NCT01475565
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance, Insulin Sensitivity, Obesity, Pregnancy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

NCT03152591
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Springfield, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Implementing Digital Health in a Learning Health System

NCT03713333
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Heart Failure, Atrial Fibrillation, Metabolic Syndrome, Genetic Disease
Interventions
Digital Health Device Diagnostics
Diagnostic Test
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 26, 2026, 4:15 PM EDT
Terminated Not applicable Interventional

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT02052479
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 26, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Sep 26, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
Drug
Lead sponsor
Rezolute
Other
Eligibility
2 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

NCT00674440
View directory record Official record
Conditions
Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy, CHI, PHHI
Interventions
F-DOPA, PET scan
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 26, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bisphenol A and Muscle Insulin Sensitivity

NCT03771066
View directory record Official record
Conditions
Insulin Sensitivity, Glucose Metabolism Disorders, Microtia
Interventions
bisphenol A, Placebo
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 26, 2026, 4:15 PM EDT